Shift Biosciences announces key appointments to advance rejuvenation therapeutics pipeline

FHS
March 12, 2025
10:50 am

Shift Biosciences, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the appointments of Jill Reckless, Ph.D, as Translation Advisor and Laurence Reid, Ph.D., as Non-Executive Director. In these roles, Jill and Laurence will guide Shift in building a robust product translation and business development strategy respectively, enabling the Company to capitalize on early momentum and progress its pipeline of novel rejuvenation therapeutics towards clinical development.

England’s MMR vaccinations up 23% following NHS initiative – Pharmaceutical Technology

Share this article Vaccinations were up four fold in those aged five to 25 years old. Image credit: Shutterstock/didesign021. England’s NHS is calling its recent

April 5, 2024

Small Solutions for Big Problems in Drug Discovery and Delivery

Ijeoma Uchegbu discusses nanomedicine’s role in improving medication adherence and developing non-addictive pain relief solutions at ELRIG Drug Discovery 2024.

November 19, 2024

FDA accepts Sobi’s Gamifant application for HLH/MAS treatment

Sobi’s Gamifant was previously approved by the US regulator in 2018. © Swedish Orphan Biovitrum AB. The US Food and Drug Administration has accepted Sobi’s

February 28, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.